Gemcitabine/Cisplatin
Phase 3Small molecule
AstraZenecaGemcitabine/Cisplatin is one of 170 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.
6
Indications
16
Total Trials
6
Active Trials
169
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Gemcitabine/Cisplatin
AstraZenecaPhase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Biliary Tract Cancer4 trials
Non-Small Cell Lung Cancer4 trials
Breast Cancer3 trials
Nasopharyngeal Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemcitabine/Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company